SCHEMBL6455822

SCHEMBL6455822

N[C@H]1CC[C@@H](NC(=O)c2ccc(OC(F)(F)F)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 6/20 0.58
DPP4 P27487 1/20 0.56
DPP8 Q6V1X1 1/20 0.56
DPP9 Q86TI2 1/20 0.56
DPP7 Q9UHL4 1/20 0.56
MCHR1 Q99705 1/20 0.54
ST14 Q9Y5Y6 5/20 0.54
PRSS1 P07477 3/20 0.54
PRSS2 P07478 3/20 0.54
PRSS3 P35030 3/20 0.54
F2 P00734 3/20 0.54
EPHX2 P34913 6/20 0.53
FAAH O00519 5/20 0.53
RAF1 P04049 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.51
F10 P00742 1/20 0.51
EPHX1 P07099 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6455818 1.00 SMYD3 (0.58) SMYD3DPP4DPP8DPP9DPP7
SCHEMBL3678482 0.93 MCHR1 (0.60) DPP4DPP8DPP9DPP7MCHR1
SCHEMBL11820779 0.87 MCHR1 (0.55) DPP4DPP8DPP9DPP7MCHR1
SCHEMBL11814856 0.83 EPHX2 (0.52) DPP4DPP8DPP9DPP7MCHR1
SCHEMBL24360439 0.81 SMYD3 (0.62) SMYD3ST14PRSS1PRSS2PRSS3
SCHEMBL24360441 0.81 SMYD3 (0.62) SMYD3ST14PRSS1PRSS2PRSS3
SCHEMBL4590917 0.80 TAS1R3 (0.59) SMYD3MCHR1ST14PRSS1PRSS2
Hydrochloric Acid SCHEMBL27207691 0.80 SMYD3 (0.61) SMYD3DPP4DPP8DPP9ST14
SCHEMBL3809790 0.79 NPC1 (0.71) SMYD3MCHR1
SCHEMBL24359915 0.79 NPC1 (0.71) SMYD3MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101475528-A Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO LTD (JP) 2009-07-08 CN disclosed
CN-100451004-C Pyrimidine derivatives ARENA PHARM INC (JP) 2009-01-14 CN disclosed
CN-1798736-A Novel quinoline, tetrahydroquinazoline and pyrimidine derivatives and methods of treatment related to their use ARENA PHARM INC (JP) 2006-07-05 CN disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 SMYD3 929/4885DPP4 358/4885DPP8 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.